Products
Canrivitug Biosimilar Monoclonal Antibody (SARS-CoV-2 RBD) for Research
Cat No.: GMP-Bios-INN-1123
Anti-SARS-CoV-2 RBD therapeutic antibody (Pre-made Canrivitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Canrivitug is a human monoclonal antibody targeting the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Further development details are under investigation.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1123-1mg | 1mg | 3090 |
| GMP-Bios-INN-1123-10mg | 10mg | |
| GMP-Bios-INN-1123-100mg | 100mg | |
| GMP-Bios-INN-1123-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Canrivitug biosimilar, Whole mAb: Anti-SARS-CoV-2 RBD therapeutic antibody |
| INN Name | Canrivitug |
| Target | SARS-CoV-2 RBD |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | TBC |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | SARS-CoV-2 Infection |
| Production | na |
| Development Tech | na |
